8-KAccepted Nov 16, 7:02 AM ET
Lexeo Therapeutics: reports results for 3 and 9 months ended Sep 30, 2026
Accepted (ET)
7:02 AM
Nov 16, 2026
Filed
Nov 16, 2026
Documents
71
Size
28.9 MB
Summary
Lexeo Therapeutics: reports results for 3 and 9 months ended Sep 30, 2026
What happened
- On Nov 16, 2026, Lexeo Therapeutics, Inc. issued a press release announcing business highlights and its financial results for the 3 and 9 months ended Sep 30, 2026. The filing says a copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference.
- The filing says the corporate presentation to be used in connection with the webcast described in the filing was furnished as Exhibit 99.2 (LX2020), dated Nov 16, 2026, and Exhibit 99.3, dated Nov 16, 2026.
Key details
- Press release issued Nov 16, 2026 announcing business highlights and financial results for the 3 and 9 months ended Sep 30, 2026; furnished as Exhibit 99.1.
- Corporate presentation dated Nov 16, 2026 furnished as Exhibit 99.2 (LX2020) and Exhibit 99.3.
- Report filed Nov 16, 2026 and signed by R. Nolan Townsend, chief executive officer.
- Items reported include Item 2.02 (results of operations and financial condition), Item 7.01 (Regulation FD disclosure), and Item 8.01 (other events).
Why it may matter
- Item 2.02 covers the company’s results of operations and financial condition as disclosed in the Nov 16, 2026 press release. Item 7.01 covers Regulation FD disclosure in the form of the corporate presentation for a webcast. Item 8.01 covers other events referenced in the report. A filing does not show why the insider traded or why the company acted.